The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 329:51-53 July 1, 1993 Number 1
NextNext

Digoxin in Heart Failure

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
Although two centuries of anecdotal clinical evidence support the use of cardiac glycosides for the treatment of heart failure, controversy has surrounded their efficacy and appropriate indications. Early in this century, two of the founders of the clinical discipline of cardiology, Sir James Mackenzie in London and Henry Christian in Boston, had sharply differing views that have tended to persist in the United Kingdom and the United States, respectively. Mackenzie advocated the use of digitalis only in patients with supraventricular tachyarrhythmias, such as atrial fibrillation, whereas Christian believed that "digitalis . . . has a striking effect on those changes . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.